A recent racing digest carried a piece of news: one Lorenzo Loffler, "architect of a doping program in Formula 1," had been disqualified. It sounded weighty — like a headline from the era of "Operación Puerto." I went to check the name — and hit a wall. No search index knows of a Doctor Loffler: there's a French entrepreneur born in 1995 from Illkirch who runs an ambulance service and a restaurant, but he has no connection to the paddock. No sport, no doping, no such surname in the FIA anti-doping committee's list of decisions.
Since the lead didn't pan out, the vacuum around it became more interesting. Since 1950, when the world championship started, Formula 1 has had not one confirmed violation of anti-doping rules. Not "few." Zero. In cycling during this time, doping burned the careers of hundreds, in track and field — dozens, while motorsport, where people at 300 km/h do what would kill an ordinary person in a minute, turned out to be the only major sport in which anti-doping discipline was never violated. This doesn't happen — or it does, and that's worth understanding.
Let's start with what destroys the most popular objection — "drivers don't need doping, it's a sport of engines, not bodies." Science says otherwise: the driver's body works at its limit. Heart rate in a race stays at levels characteristic of marathon runners, while the physical work is different — static, with loads up to 5g in corners. Before the 2013 season, Fernando Alonso cycled 936 kilometers, ran 91, swam 81, and spent seven hours in the gym — in three weeks. Ferrari then called this regime "worthy of an Olympian."
But here's what a fresh systematic review of F1 driver physical preparation, published in the British Journal of Sports Medicine in early 2026, discovered: in aerobic fitness, height, and body mass, Formula 1 drivers are not exceptional athletes. The only pronounced adaptation to cockpit specifics — strengthened neck muscles that hold the head under g-forces. The authors honestly admit: a significant portion of training practice is built on coaches' experience and anecdotal observations, not data.
From this follows a non-obvious conclusion. Classic power doping — erythropoietin, anabolic steroids, blood transfusions — targets qualities drivers already have sufficiently developed through training. The pharmacological target in Formula 1, if it exists at all, is narrow: thermoregulation, concentration, neck. So narrow that doctors even debate whether it exists at all.
The historical picture is completely different from the modern one. In the 1950s, stimulants in racing were the norm, like morning coffee. Stirling Moss admitted in an interview with Italian magazine Quattroruote that he won the 1955 Mille Miglia — his legendary victory in a Mercedes 300SLR with a course record — on pills that Juan Manuel Fangio gave him before the start. "I don't know what was in those pills, but they definitely worked. Today they would definitely be banned substances," Moss said. According to him, everyone took them then.
What those pills were was unearthed by Motor Sport Magazine readers half a century later. According to Moss's book about Fangio, the Argentine's doctor prescribed him drugs against exhausting thirst in long races in the heat. Moss recorded the name in his diary — Dynavis, manufactured by Vister from Switzerland. Moss's father, a meticulous man, sent one pill for analysis — and the lab found an "unidentifiable ingredient" there. What it actually was, no one knows: amphetamine, caffeine cocktail, or placebo with iron will.
After that era, the rules changed. Amphetamines, sold in pharmacies without prescription, became prescription-only in 1956. Another ten years later, British doctors were prescribing 5.5 million doses a year — and sport gradually began tightening the screws. But motorsport joined this wave later than all others, about which — below.
In seventy-six years, two loud doping accusations have been made against Formula 1. Both crumbled at the first check — and that's precisely why they're instructive.
The first came in 2005 from Dr. Benigno Bartoletti, a 68-year-old former Ferrari doctor. In an interview with the same Quattroruote, he stated that up to a third of the twenty Formula 1 drivers take cocaine as a stimulant before races — supposedly the substance sharpens reaction and gives a feeling of invincibility. The paddock reacted instantly and with nervous laughter: Mark Webber called the statement "absolutely comical," Jean Alesi — "laugh-inducing." The official background objected in unison: German Sport Bild reported that the FIA conducted over 50 doping tests in 2004, and all were negative — random samples were taken after every Saturday qualifying, Michael Schumacher was tested twice. The cocaine "third of the paddock" left no trace in the samples.
The second happened in 2013, against the backdrop of the escalating French doping investigation in cycling. Marc Sanson, who headed the French anti-doping council in 2003–2005, stated that F1 drivers had been taking tacrine for years — a drug against Alzheimer's disease — to more easily memorize track configurations. The idea of "memory doping" sounded novel, but shattered against the facts. Dr. Gary Hartstein, the FIA's longtime medical delegate, called Sanson on Twitter a "loud ignoramus seeking a headline" and clarified: tacrine is not and never was on WADA's prohibited list — at that time the list ran nine pages, and tacrine wasn't in it at all. "If a drug isn't on the list, you can take it every day — it may be stupid, but it's not doping," Hartstein summed up. Then he added physiology: tacrine doesn't even work for those it's prescribed to, it has a mass of side effects, and if it were effective, there'd be a line of everyone over fifty at therapists' offices.
After these two episodes, new accusations against F1 simply stopped being made. Sanson and Bartoletti exhausted the genre.
Real doping cases in motorsport did exist, of course — but they all lie either outside Formula 1 or in the zone of so-called recreational substances that don't provide racing advantage.
The loudest — Tomáš Enge, a Czech driver who managed to run several races for Prost in the 2001 championship. In 2002 he won the title in International Formula 3000, but in a sample taken at the Hungary weekend, they found traces of cannabis. The FIA annulled his result in Hungary — and Enge became the first champion in motorsport history stripped of a title due to a doping test. The championship went to Sébastien Bourdais. Tellingly, Enge himself said: "I fully respect the decision."
Ten years later, history repeated itself more harshly: in 2012 at an FIA GT1 round in Navarra, his sample showed levmetamphetamine and amphetamine — classic stimulants from section S6 of the WADA list. The FIA gave 18 months, the Court of Arbitration for Sport in Lausanne rejected the appeal in 2013. But that was GT1, not F1, and the only such case in the entire history of the FIA.
The rest — a sad anthology of the same genre. Franck Montagny, former Super Aguri driver, got two years in 2016 for benzoylecgonine — a cocaine metabolite — in a sample after a Formula E race in Putrajaya. Jeremy Mayfield became in 2009 the first NASCAR driver disqualified under the series' anti-doping policy: methamphetamine, scandal, court, return and dismissal. Aaron Fike in 2007 admitted he used heroin during race weekends. Even Tarso Marques, ex-Minardi driver, managed to get two years for anabolic steroids — but that happened already in the Brazilian touring car championship, outside F1.
The common denominator in all these stories is one: not one was an attempt to improve racing results. Motorsport "catches" racers on the same things it catches ordinary people — on personal weaknesses, not on constructed doping programs.
Now about why this happened. The anti-doping system in motorsport is the youngest among major disciplines. WADA appeared in 1999, but the FIA integrated its rules late: Appendix A to the International Sporting Code, introducing full anti-doping according to WADA standards, came into force only December 1, 2010. For comparison: track and field lived by the WADA code from its very appearance. In Formula 1, the full transition with out-of-competition testing was announced only in March 2010, at the Bahrain Grand Prix — FIA vice president for sport Graham Stoker then reassured the public that the transition would be "relatively painless."
The scale of testing is laughable compared to cycling. According to official FIA statistics for 2022, in- and out-of-competition tests in FIA championships totaled 116 in-competition and 47 out-of-competition (of which 33 successfully completed). Nine therapeutic use exemption applications. Zero violations. The entire world motorsport championship, all series, all drivers — fewer tests than one Tour de France prologue collects in a week. Even Mark Webber, far from the most cautious person in the paddock, admitted in 2013 that after the German Grand Prix they took a blood sample from him for the first time in his career — and this was good news because "you can't trust every person in the paddock."
And yet the paradox: a system with such holes hasn't let through a single case. Why? The first part of the answer is economics. A driver costs tens of millions of dollars a year, the team invests hundreds, and any performance spike, like Verstappen's in 2023 or Hamilton's in the hybrid era, is explained by the car, not the blood. Sports where doping survives are sports where the result is controlled by the body: running, cycling, weightlifting. In F1 the body is only the second multiplier after the car, and buying the second multiplier with a broken first is pointless.
The second part — cockpit physiology. During the infamous 2023 Qatar Grand Prix, the temperature inside the cars, according to George Russell, approached 60 degrees, drivers lost up to four kilograms of weight per race, Esteban Ocon vomited in his helmet, and Lance Stroll was on the verge of losing consciousness. Amphetamine-class stimulants accelerate pulse, intensify dehydration, and suppress the feeling of thirst — in a cockpit that itself works like a sauna, this isn't "performance enhancement," it's a ticket to heat stroke at 300 km/h. FIA medical delegate Jean-Charles Piette framed it fundamentally: if a footballer takes something prohibited, he himself suffers; if a driver does the same, the threat extends to colleagues on track, marshals, and spectators. Racing is a sport where the price of doping risk is higher by orders of magnitude, because error there is measured not in seconds but in lives.
Back to Loffler. The story of an "architect of a doping program in F1" sounds plausible precisely because in reality there's a void: not one case in 76 years, not one test in the FIA anti-doping decisions list. In such a void, any headline must carry proof — name, date, decision number, court. Checking all available indexes — English and Russian, by search engines and sports federation archives — finds nothing: no Loffler in motorsport, no doping program, no disqualification. There's only the skeleton of a story, indistinguishable from what a language model generates when asked to invent a "fresh scandal in Formula 1": plausible surname, plausible position, zero sources.
Perhaps the news does exist after all — fresh events enter search indexes with a delay, and in a month it might surface in regional press. I'll say honestly: I don't know. But the very possibility of an invented "doping scandal in F1" is the best illustration of the topic. In seventy-six years the paddock taught the world one thing: in racing, doping either doesn't work, or kills whoever takes it, or crumbles at the first check, as Bartoletti and Sanson crumbled. The Loffler story, if it's real, would be the first of its kind. If it's not real — it fits perfectly into tradition: there have never been doping scandals in Formula 1, including those written about in the news.